Moreover, higher ARPC1A was associated with poorer PFI in LGG, UVM, ACC, STAD, KIRC, and MESO patients, while the opposite effect was seen in READ patients (Figure S3B). Here, ARPC1A is linked to gastric adenocarcinoma.